Steven Sternthal

Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations Food and Drug regulations as it relates to data protection and the regulation and protection of biopharmaceutical products Canada's Drug Agency (CDA) policies as it relates to health economics assessment and recommendations made on new medicines. Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations. Free Trade agreements as they relate to the biopharmaceutical industry Policy and Programs Health Canada and Public Health Agency of Canada policies and programs to prevent and treat HIV and eliminate hepatitis as a public health threat by 2030, as part of Canada's commitments under the Global Viral Hepatitis Strategy and therapeutic efforts against the fight for COVID-19. Patent Act Regulations as they relate to the regulation of intellectual property for therapeutic products, specifically the Patented Medicines (Notice of Compliance) Regulations Patented Medicine Prices Review Board (PMPRB) Regulations with regard to reporting requirements, pricing, guidelines and dispute resolution. Innovation Agenda, particularly with respect to initiatives to support and attract investments in the life sciences sector Federal Government First Nations and Inuit Health Branch program with respect to health services. Federally-funded Public Drug Plans, with respect to reimbursement for drug products for federal plan beneficiaries.

Policy and Programs Health Canada and Public Health Agency of Canada policies and programs to prevent and treat HIV and eliminate hepatitis as a public health threat by 2030, as part of Canada's commitments under the Global Viral Hepatitis Strategy and therapeutic efforts against the fight for COVID-19. Patent Act Regulations as they relate to the regulation of intellectual property for therapeutic products, specifically the Patented Medicines (Notice of Compliance) Regulations Patented Medicine Prices Review Board (PMPRB) Regulations with regard to reporting requirements, pricing, guidelines and dispute resolution. Innovation Agenda, particularly with respect to initiatives to support and attract investments in the life sciences sector Federal Government First Nations and Inuit Health Branch program with respect to health services. Federally-funded Public Drug Plans, with respect to reimbursement for drug products for federal plan beneficiaries. Canada Agency for Drugs and Technologies in Health (CADTH) as it relates to health economics assessment and recommendations made on new medicines.

Viral hepatitis, with respect to federal screening guidelines, data collection, harm reduction funding and policy, testing technology, and prevention, testing, and treatment for people under federal jurisdiction.

Engage with government to strengthen the Priority Review of Drug Submissions process. The Government of Ontario has passed legislation requiring the public disclosure of payments made to Health Care Providers and Health Care Organizations by the broader health care industry, including pharmaceutical companies, generic manufacturers, and medical device companies. GlaxoSmithKline seeks to advocate for a national approach to disclosure through either the support of similar provincial initiatives, coordinated action through the Federal / Provincial and Territorial meetings of the Ministers of Health, and / or the establishment of national requirements. Sharing information with government and Members of Parliament on different models for national pharmacare, specifically as it relates to access to medicines. Renewal of national vaccine strategy to close gaps in vaccination coverage for Canadians, especially among seniors. Reforms to the Patented Medicines Review Board (PMPRB), whose guidelines seek to ensure a balance between the prices set by manufacturers for patented medicines sold in Canada and the maintenance of an attractive environment for pharmaceutical research and development. Specifically with regard to ensuring that any actions and proposed changes by the PMPRB do not negatively impact access to patented medicines in Canada. Raise awareness regarding the potential risks to drug and vaccine supply for Canadian patients arising from new U.S. state-level reimportation legislation. Participation in consultations regarding the Digital Charter and the federal government's plans to overhaul Canada's privacy regime, to enable the use of anonymized health data for new medication research and development. Input on the work of the Advisory Committee on the Implementation of National Pharmacare, specifically as it relates to access to medicines. Ensure the National Advisory Committee on Immunization has sufficient resources to undertake timely reviews of new vaccines that are made available to the Canadian marketplace. Engaging Health Canada on the Self-Care Products Initiative as it pertains to plain language labelling and a risk-based approach to regulatory oversight for non prescription drugs. Engage the government regarding the need for clear and efficient procurement processes for COVID-19 medical countermeasures, including COVID-19 therapeutics, to ensure access for Canadians. Engage government officials regarding domestic manufacturing of seasonal and pandemic flu vaccine. Antimicrobial Resistance (AMR) - Identification of the need for a multi-sectoral stakeholder working group to pursue joint goals under a Pan-Canadian AMR strategy and to strengthen Canada's end-to-end research capacity in AMR.

Criminal Code R.S.C. 1985, c. 46 Our interest is in ensuring that this law and its application in practice does not discriminate against people living with HIV or impede access to prevention information, tools and services on Human Immunodeficiency Virus (HIV). Immigration and Refugee Protection Act, S.C. 2001, c. 27 Our interest is in ensuring that this law and its application in practice does not discriminate against people living with HIV and other health conditions. Criminal Code R.S.C. 1985, c.46 Our interest is in ensuring that this law and its application in practice does not impede access to prevention information, tools and services (for example needle distribution programs, supervised consumption services, Opioid Agonist Treatment) on the Human Immunodeficiency (HIV), hepatitis C virus (HCV) and other health services for people who use drugs. Criminal Code, R.S.C 1985, c.46 Our interest is in ensuring that provisions of this statute dealing with sex work do not undermine the health, safety and other human rights of sex workers, including in relation to HIV. Corrections and Conditional Release Act, S.C. 1992, c.20 Our interest is in ensuring that this legislation facilitates access to prevention information tools and services on the Human Immunodeficiency Virus (HIV), hepatitis C virus (HCV) and facilitates access to adequate care, treatment and support for prisoners with HIV or HCV. Controlled Drugs and Substances Act, S.C. 1996, c. 19 Our interest is in ensuring that this law and its application in practice, does not impede access to prevention information, tools and services (eg. needle distribution programs, supervised consumption services, Opioid Agonist Treatment) on the Human Immunodeficiency Virus (HIV), hepatitis C virus (HCV) and other health services for people who use drugs. Case for increasing funding to the Federal Initiative to Address HIV/AIDS in Canada, and community concerns about the roll-out of the Community Action Fund under said Federal Initiative.

Increases to the International Assistance Envelope Allocations of the International Assistance Envelope Advocating spending priorities related to the dissemination of Canada's Official Development Assistance envelope to ensure that aid is targetted at initiatives that serve the world's poorest. Advocating for increased investment toward tuberculosis elimination, specifically through the creation of a national tuberculosis elimination strategy.

Health Canada and Public Health Agency of Canda policies and programs to prevent and treat HIV and meet global agreement terms to end the HIV epidemic by 2030. This includes, new or increased grants/contributions to community?based testing, linkage, harm reduction and priority population programs